## CLINICAL TRIAL

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
	A Multicenter, Prospective, Randomized, Open-			
	Label, Two-Arm, Parallel-Group, Phase III, Active			
Dr. Kishan	Controlled, Non-inferiority, Comparative Study to	Raptim Research		
Ninama	Assess Efficacy and Safety of Tofacitinib Ointment	Pvt ltd	2022-2023	1.08
Ivillallia	2% w/w to Pimecrolimus Cream $1%$ w/w in	i vi itu		
	Patients with Mild to Moderate Atopic Dermatitis			
	(AD).			
	A Randomized, Double-masked, Parallel-group,			
Dr. Punit	Multicenter Clinical Study to Evaluate the Efficacy	IQVIA RDS		
Singh	and Safety of AVT06 Compared with EU-Eylea $\ensuremath{\mathbb{R}}$ in	(INDIA) Private	2022-2023	2.21
Siligii	Subjects with Neovascular (wet) Age-related	Limited		
	Macular Degeneration (ALVOEYE).			
	Phase II, Multicenter, Randomized, Assessor-blind,	Zydus Lifesciences Limited		
	Parallel-group, Active- comparator Study to		2022-2023	0.81
Dr J D Lakhani	Determine the Efficacy, Safety, Tolerability, and			
DI J D Lakilalli	Pharmacokinetics of Different Orally Administered			
	Regimens of ZY-19489 in Uncomplicated			
	Plasmodium Falciparum Malaria Patients.			
	Randomized, Double-Blind, Placebo-Controlled,			
	Parallel-Group, Multi-Centre Phase II/III Adaptive		2021-2022	
Dr. Arti Chah	Clinical Trial to Assess the Safety and	ICC Madiaal		48.2
Dr. Arti Shah	Immunogenicity of Gam-COVID-Vac Combined	JSS Medical		48.2
	Vector Vaccine for SARS-Cov-2 Infection in Indian			
	Healthy Subjects.			
	A prospective, randomized, parallel, multicentric,			
	Phase-III clinical trial of Molnupiravir 800 mg			
Dr. Arti Shah	capsules and standard of care (SOC) compared to	CBCC	2021-2022	1
	standard of care only in confirmed RT-PCR positive			
	patients with mild COVID-19.			

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
Dr. Kishan Ninama	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Cliantha Research Ltd Opp. Pushparaj Towers, Nr. Judges Bungalows, Bodakdev, Ahrnedabad - 380 054, India	2021-2022	0.75
Dr. Rashmi Mahajan	A Randomized, Double-blind, Multicentric, Parallel- group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Adapalene 0.1% and Benzoyl peroxide 2.5% G el (Morningside Healthcare Ltd, UK) versus EPIDUO 0.1%/2.5% Gel (Galderma U.K Ltd) in Subjects with Acne Vulgaris.	Cliantha Research Ltd	2021-2022	0.51
Dr. Punit Singh	Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.	IQVIA RDS (INDIA) Private Limited	2021-2022	0.5
Dr. Sadhna Kumari	Evaluation of safety and efficacy of Energy Booster on the physical endurance and fitness in healthy subjects.	Krish Herbs	2021-2022	0.33
Dr. Sadhna Kumari	Evaluation of safety and efficacy of Happy Pill in healthy subjects.	Krish Herbs	2021-2022	0.33
Dr. Rashmi Mahajan	A randomized, multicenter, double blind, placebo controlled, triple-arm parallel study to evaluate bioequivalence of Adapalene and benzoyl peroxide gel, 0.3%/2.5% (Cipla) with EPIDUO® FORTE (adapalene and benzoyl peroxide) gel, 0.3%/2.5% (GALDERMA LABS) in human subjects with acne vulgaris.	Cipla Ltd Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013	2019-2020	0.75

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
	A Phase 3, Multicenter, Multi-country, Open-label,	Cadila Health Ltd		
	Randomized, Active-controlled Clinical Trial to	Zydus Towers,		
Dr Harshal	Evaluate the Efficacy and Safety of Desidustat	Satellite Cross	2010 2020	13.14
Joshi	Versus Darbepoetin for the Treatment of Anemia in	Roads,	2019-2020	15.14
	Patients with Chronic Kidney Disease (CKD) who	Ahmedabad-		
	are not on Dialysis.	380015, India		
	Immunogenicity and Safety of an Investigational			
Dr. Prasad	Quadrivalent Meningococcal Conjugate Vaccine in			
	Healthy Adults, Adolescents, and Children in India	IQVIA	2019-2020	0.75
Muley	and Healthy Adolescents and Children in the			
	Republic of South Africa.			
	A Prospective, Randomized, Parallel Group, Double			
Dr. Punit	Blind, Multicenter Study to Compare the Efficacy,			
Singh	Safety & Immunogenicity of Lupin's Ranizumab	Lupin Limited	2019-2020	5.89
Jiligii	with Lucentis $\ensuremath{\mathbb{R}}$ in Patients with Neovascular Age-			
	Related Macular Degeneration.			
Dr Hetal	A Multicenter, Open-Label, Single-Arm, Phase 4			
Pnadya	Study to Assess the Safety of Basaglar in Subjects	IQVIA	2019-2020	3.09
Thadya	with Type 2 Diabetes Mellitus in India.			
	A Prospective, Multi-center, Randomized, Double-			
	blind, Parallel-group, Comparative clinical endpoint			
	bioequivalence study to compare the efficacy and			
	safety of generic Fluticasone propionate inhalation	Macleods		
Dr. Arti Shah	aerosol (pMDI) (of Macleods Pharmaceuticals Ltd)	Pharmaceuticals	2019-2020	1.35
	versus FLOVENT HFA (pMDI) inhalation aerosol	Ltd		
	and efficacy and safety of both test and RLD to a			
	placebo-control in treatment of patients with			
	bronchial asthma.			
	A Pivotal, Multiple-Dose, Pharmacokinetic	CBCC Global		
	Bioequivalence Trial Comparing Generic to	Research		
Dr Lakhan	Reference Listed Drug of Paliperidone Palmitate	2nd Floor, Skoda	2019-2020	0.75
Kataria	Extended-Release Injectable Suspension (156 mg)	House,		
	in Subjects with Schizophrenia or Schizoaffective	Opposite L J		
	Disorder.	Campus, S G		

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
		Highway,		
		Ahmedabad		
		382210, Gujarat		
		bd@cbcc.global		
		+91 79 68221800		
	A multi-center, double-blind, randomized, parallel			
Dr. Rashmi Mahajan	group, active and placebo-controlled in vivo clinical endpoint based bioequivalence study of Clindamycin Phosphate Topical Lotion Eq. 1% Base among subjects with Acne Vulgaris.	Raptim Research Pvt Ltd	2019-2020	10.22
Dr. Punit Singh	A multicenter, randomized, assesor blided, active controlled, parallel group, two arm, bioquavalence study with clinical end point between brinzolamide 10mg/ml plus brimonidine tartarate 2mg/ml eye drops suspensions (pharmathen S.A, greece) and simbrinza® (Brinzolamide 10mg/ml plus brimonidine tartarate 2mg/ml) eye drops suspension (Novartis euro pharm Ltd, Ireland) in the treatment of elevated intraocular pressure in adult patients with open angle glucoma or ocular hyper tension.	Veeda Clinical Research Ltd	2019-2020	18.24
Dr. Arti Shah	A Double Blind Multi-center, Two Arm, Randomized, Placebo, Controlled, Phase III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin Alpha-1 as an add on Treatment of to existing standard of care treatment in Moderate to Severe COVID-19 Patients.	iDD Research solutions Pvt Ltd	2019-2020	0.75
Dr. Kishan Ninama	A Multicentre, Double Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo ® Forte (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) and both Active	Cadila Pharmaceuticals "Cadila Corporate Campus", Sarkhej - Dholka Road, Bhat, Dist.	2019-2020	13.87

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
	Treatment of Acne Vulgaris.	Ahmedabad		
Dr. Arti Shah	A randomized, open-label, two way crossover study to compare inhalation flow profiles generated with medication-free generic tiotropium bromide inhalation device of Cipla Ltd. India and SplR VA HANDIHALER device of Boehringer Ingelheim Pharmaceuticals, Inc., USA in healthy adult subjects and adult sub.iects with moderate, severe and very severe chronic obstructive pulmonary disease.	SIRO Clinpharm	2019-2020	1
Dr. Arti Shah	A Phase III, Randomized, Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b In the Treatment of Adult Patients Diagnosed With SARS-CoV-2 (COVID- 19).	Cadila Healthcare Ltd Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad, Gujarat, India	2019-2020	1
Dr. Arti Shah	Phase IIb study to evaluate the efficacy and safety of Sofosbuvir/Daclatasvir (SOF/DCV) with or without Nitazoxanide in combination with standard of care in adult patients with moderate Covid-19.	JSS Research India Pvt Ltd	2019-2020	1
Dr. Prasad Muley	A single blind randomized active-controlled Phase- III study to evaluate immunogenicity, safety, tolerability of a candidate 14-valent pneumococcal polysaccharide conjugate vaccine administered to 6-8 weeks old healthy Indian Infants in 6-10-14 weeks dosing schedule.	Biological E. Limited Road No. 35, Jubilee Hills Hyderabad, Telangana -	2019-2020	0.75

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
		500033		
		91-40-7121		
		6000		
		91-40-7121 6064		
		/ 6332		
		info@biologicale.c		
		om		
		Axis Clinicals		
		1-121/1, Survey		
	A multicentre, double-blind, randomized, single-	No.66 (Part) &		
	A multicentre, double-bind, randomized, single- period, placebo-controlled, parallel group study of Adapalene 0.1% and Benzoyl Peroxide 2.5% Topical Gel of BELUPO Inc., Croatia (Test) and Epiduo Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5%) (Reference) of Galderma (EU) in subjects with mild to moderate facial acne vulgaris.	67(Part),		
		Miyapur,		
Dr. Kishan		Serilingampally,	2019-2020	8.56
Ninama		Hyderabad	2019-2020	0.50
		500049, India		
		Mail:		
		abhijit.chaudhari		
		@axisclinicals.co		
		m		
	A Randomized, Double-blind, Multicenter, Three-	Cliantha Research		
	arm, Active and Placebo-controlled, Parallel Study	Ltd		
	to Evaluate the Bioequivalence (with Clinical	Opp. Pushparaj		
Dr. Kishan	Endpoint) of Mupirocin Cream USP, 2% (Cadila	Towers, Nr.		
Ninama	Healthcare Ltd, India) to Mupirocin Cream USP, 2%	Judges	2019-2020	4.36
Milallia	(Glenmark Pharmaceuticals Inc., USA) in Subjects	Bungalows,		
	with Secondarily Infected Traumatic Skin Lesions	Bodakdev,		
	(Protocol No: CRL071934).	Ahmedabad - 380		
	(FIOLOCOLINO, CKEO/1754).	054, India		
	A Multicentre, Randomized, Double-Blind, Double-	Cliantha Research		
	Dummy, Three-Arm, Placebo Controlled, Parallel	Ltd		
Dr. Rashmi	Adaptive Phase III Clinical Study to Evaluate the	Opp. Pushparaj	2019-2020	4.93
Mahajan	Efficacy and Safety of Dimethyl Fumarate Gastro-	Towers, Nr.	2019-2020	4.75
	Resistant Hard Capsule of Alvogen Malta (Out-	Judges		
	Licensing) Ltd with Fumaderm® Gastro-Resistant	Bungalows,		

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
	Tablet of Biogen GmbH in Subjects with Moderate to	Bodakdev,		
	Severe Chronic Plaque Psoriasis.	Ahrnedabad - 380		
		054, India		
Dr. Prasad Muley	Phase III Safety and Immunogenicity of an Investigational versus Existing Formulation of the Licensed Pentavalent Vaccine (DTwP-HepB-Hib) Shan 5® when administered as Three Dose Primary Series at 6-8, 10-12 and 14-16 Weeks of Age in Healthy Indian Infants and Immunogenicity of the Investigational Shan 5® Formulation when administered as a Single Booster Dose at 12-24 Months of Age.	Shantha Biotechnics Private Limited	2018-2019	8.18
Dr Vipul Gujar	Multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension- avoidance strategy.	St. John's Research Institute	2018-2019	0.37
Dr. Kishan Ninama	A Phase III, multicentre, randomized, observer blind, parallel group, three arms, controlled clinical trial to evaluate the efficacy and safety of topically applied Calcipotriol/AKVANO 50 μg/g cutaneous solution against Calcipotriol Ointment 50 micrograms/g, Sandoz and placebo in patients with mild to moderate plaque psoriasis.	Cadila Pharmaceuticals "Cadila Corporate Campus", Sarkhej - Dholka Road, Bhat, Dist. Ahmedabad	2018-2019	15.09
Dr. Arti Shah	A Phase IV, Prospective, Open Label, Non- Comparative, Multicenter Study With 24 Weeks of Treatment Period To Assess Safety, Tolerability And Efficacy Of Pirfenidone 200mg Oral Tablets In Patients With Idiopathic Pulmonary Fibrosis (IPF).	Cipla Ltd Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013	2018-2019	4.4

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
	A Randomized, Placebo Controlled, Assessor-Blind,			
	Parallel Group, Comparative Clinical Endpoint	Sun		
Dr. Arti Shah	Bioequivalence Study of Two Formulations of	Pharmaceutical	2018-2019	0.75
	Fluticasone Propionate HFA (44 mcg) Inhalation	Industries Ltd.		
	Aerosols in Patients with Asthma.			
		Cliantha Research		
	A Randomized, Double-blind, Multicentre, Parallel-	Ltd Opp.		
	group, Active and Placebo Controlled, Three Arm	Pushparaj		
Dr Som	Clinical Study to Compare the Efficacy and Safety of	Towers, Nr.		
Lakhani	Adapalene 0.1% and Benzoyl peroxide 2.5% Gel	Judges	2018-2019	10.83
	(Morningside Healthcare Ltd, UK) versus EPIDUO	Bungalows,		
	0.1%/2.5% Gel (Galderma U.K Ltd) in Subjects with	Bodakdev,		
	Acne Vulgaris.	Ahrnedabad - 380		
		054, India		
	A Randomized, Double-Blind, Multicenter, Three arm, Active and Placebo Controlled, Parallel Study to Evaluate the Bioequivalence (with clinical	Cliantha Research		
		Ltd		
		Opp. Pushparaj		
Dr Som	endpoint) of Adapalene and Benzoyl Peroxide Gel,	Towers, Nr.		
Lakhani	0.3%/2.5% (Cadila Healthcare Ltd, India) to	Judges	2018-2019	10.55
Lakilalli	EPIDUO <sup>®</sup> FORTE (Adapalene and Benzoyl Peroxide)	Bungalows,		
	Gel, 0.3%/2.5% (Galderma Laboratories, L.P., USA)	Bodakdev,		
	in Subjects with Acne Vulgaris.	Ahrnedabad - 380		
	in Subjects with Ache Vulgaris.	054, India		
	A Randomized, Double-blind, Multicentre, Parallel-	Cliantha Research		
	group, Active & Placebo Controlled, Three Arm	Ltd		
	Clinical Study to Compare the Efficacy and Safety of	Opp. Pushparaj		
Dr. Kishan	Clindamycin Phosphate 10 mg/g + Benzoyl	Towers, Nr.		
		Judges	2018-2019	10.26
Ninama	Peroxide 50 mg/g Gel (Morningside Healthcare Ltd, $IK$ ) vorsus DUAC® Once Daily 10 mg/g + 50 mg/g	Bungalows,		
	UK) versus DUAC <sup>®</sup> Once Daily 10 mg/g + 50 mg/g	Bodakdev,		
	Gel (GlaxoSmithKline UK Limited) in Subjects with	Ahrnedabad - 380		
	Acne Vulgaris.	054, India		
Dr Arti Chab	A randomized, multiple-dose, double blind, placebo	Axis Clinicals	2010 2010	2516
Dr. Arti Shah	controlled, parallel group, sequential design,	1-121/1, Survey	2018-2019	35.16

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
	multicentre study to evaluate Efficacy and Safety of	No.66 (Part) &		
	Beclomethasone Dipropionate Metered Dose	67(Part),		
	Inhaler (Inhalation Aerosol) (0.04mg/ INH) in male	Miyapur,		
	and/ or female subjects with Asthma [Group I	Serilingampally,		
	(Test): Beclomethasone Dipropionate 0.04 mg/	Hyderabad		
	INH; Group II (Reference) QVAR® 40 mcg	500049, India		
	(Beclomethasonedipropionate HFA); and Group III:	Mail:		
	Placebo].	abhijit.chaudhari		
		@axisclinicals.co		
		m		
Dr Raghunandan Kothari Dr Chaitri	A Phase 3, Multi-center, Randomized, Double- Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis (SHP640_301) Randomized, Double blind, Two Arm, Comparative Controlled, Prospective Clinical Trial of <i>Mycobacterium w</i> in Combination with Standard	IQVIA Cadila Pharmaceuticals "Cadila Corporate Campus", Sarkhej	2017-2018 2017-2018	2.14
Shah	<i>Mycobacterium w</i> In Combination with Standard Therapy versus Standard Therapy Alone in Sepsis due to Gram Negative Infection (PGI_0151)	- Dholka Road, Bhat, Dist. Ahmedabad	2017-2018	2.14
Dr. Rashmi Mahajan	A Multi-Centre, Randomized, Double Blind, Parallel- Group, Comparative Clinical Trial to evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in subjects with Oropharyngeal Candidiasis (TPC-CLT-002)	ThinQ Pharma	2017-2018	4.03

Name of the consultant	Name of the Advisory /R&D consultancy/clinical trial project	Consulting/ Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
Dr Raghunandan Kothari	A Phase 3, Multi-center, Randomized, Double- Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Bacterial Conjunctivitis	IQVIA	2017-2018	0.5
Dr. Kishan Ninama	A Randomized, Double-Blind, Placebo-Controlled, Three-arm, Parallel Group, Multi-Centric, Clinical Study to Evaluate The Therapeutic Bio-Equivalence of Two Tacrolimus 0.03% Topical Ointment Formulations in adult Patients With Moderate to Severe Atopic Dermatitis.	Lambda Therapeutics	2016-2017	7.06+
Dr. Punit Singh	A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study with Clinical Endpoint comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd., for Watson Pharma Pvt. Ltd.), to Brinzolamide (Azopt®) 1% Ophthalmic Suspension of Alcon Laboratories Inc., in the treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in both the eyes.	Lotus Labs Pvt Ltd	2015-2016	36.99
Dr Dulari Gandhi	A Phase III Bridging study to evaluate Immunogenicity and safety of Pentavalent vaccine (DTwP-HepB-Hib) Shan5 (with imported pertussis) when administered as three dose primary series at 6-8, 10-12 and 14-16 weeks of age in healthy Indian Infants.	Shantha Biotechnics Private Limited	2015-2016	16.79
Dr Dulari Gandhi	APhase4/3,Open-Label,Single-Arm,MulticenterStudytoDescribetheSafetyandImmunogenicityof13-valentPneumococcalConjugateVaccineinAdults50to65YearsofAgeandinChildren6to17Years ofAgeinIndia.	ICON Clinical Research India Pvt. Ltd.	2015-2016	31.54

Page **10** of **10**